Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27551589 | 0.85 | HRH3 (0.53) | HRH3HRH4TAAR1CYP3A4MAPT | |
| SCHEMBL15390776 | 0.85 | HRH3 (0.60) | HRH3HRH4TAAR1MAPT | |
| SCHEMBL18609500 | 0.79 | HRH3 (0.49) | HRH3HRH4TAAR1CYP3A4MAPT | |
| SCHEMBL5203578 | 0.77 | ADRA1A (0.53) | HRH3HRH4TAAR1CYP3A4MAPT | |
| SCHEMBL28759658 | 0.73 | HRH3 (1.00) | HRH3HRH4TAAR1CYP3A4MAPT | |
| SCHEMBL26960858 | 0.72 | ADRA1D (0.51) | HRH3HRH4TAAR1CYP3A4MAPT | |
| SCHEMBL27986334 | 0.72 | HRH3 (0.62) | HRH3HRH4TAAR1CYP3A4MAPT | |
| SCHEMBL311076 | 0.72 | ESR1 (0.61) | CYP3A4MAPTCYP2D6 | |
| SCHEMBL31371688 | 0.72 | ESR1 (0.61) | CYP3A4MAPTCYP2D6 | |
| SCHEMBL30876036 | 0.72 | ESR1 (0.61) | CYP3A4MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | CLEXIO BIOSCIENCES LTD (IL) | 2021-10-21 | — | — | US | disclosed |
| US-20210220336-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2021-07-22 | — | — | US | disclosed |
| WO-2020016827-A1 | PURIFIED CRYSTALLINE DETOMIDINE HYDROCHLORIDE MONOHYDRATE, ANHYDRATE AND FREE BASE WITH LOW AMOUNTS OF ISO-DETOMIDINE AND OTHER IMPURITIES BY RECRYSTALLISATION IN WATER | CLEXIO BIOSCIENCES LTD. (IL) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | QDPR, DCTD, NEFM | HRH3 1943/4885HRH4 2279/4885TAAR1 2266/4885 |
| US-20210220336-A1 | TOPICAL DETOMIDINE FORMULATIONS | QDPR, DDT, DCTD | HRH3 2172/4885HRH4 1501/4885TAAR1 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.